Search

everythinglearnresearchcommunity

for

Search:↓

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

The combination treatment showed a higher response rate but no significant survival benefits.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Entospletinib effectively prevents eye and skin GVHD in mice.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Belimumab effectively controls SLE disease activity and reduces steroid use.

New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.

PEA-ENL improves skin delivery and reduces inflammation without side effects.

Elental is a good long-term treatment for Crohn's disease, similar to 6-mercaptopurine but with fewer side effects.

A woman got a skin rash from taking aceclofenac, which went away after she stopped the drug.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

OBEME effectively enhances wound healing and could be a promising carrier for skin treatments.

Biologic therapies can cause various adverse events, but allergy/immunology clinicians can manage them.

The combination of encorafenib and binimetinib caused few skin issues.

Etanercept may cause lichen planopilaris, so doctors should be cautious.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.

A woman with severe angioedema improved significantly after treatment with rituximab.

BOOST is a promising, easy-to-use treatment for diabetic foot ulcers that improves healing by reducing inflammation and promoting blood vessel growth.